// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
International scientific bodies oppose clinical heritable genome editing under current conditions
WHO, NASEM, Royal Society, Hinxton Group consensus.
Module 12 · Ethics, Equity, and the Germline Question →B
ACMG-recommended opportunistic secondary-finding return improves outcomes for some carriers
Plausible mechanism, supported by single-gene case series; controlled outcome data limited.
Module 12 · Ethics, Equity, and the Germline Question →D
Polygenic embryo screening (PGT-P) reliably and ethically improves child health outcomes
No long-term data; probabilistic re-ranking with limited absolute effect; unresolved ethics.
Module 12 · Ethics, Equity, and the Germline Question →F
GINA fully protects US patients against genomic discrimination
GINA covers health insurance and employment only; life, disability, and long-term-care insurers may use genetic information.
Module 12 · Ethics, Equity, and the Germline Question →